-
Exploratory Efficacy Data Suggests Further Study of Peanut Tolerance with Oral Mucosal Immunotherapy (OMIT)
NEW YORK, June 12, 2026 (GLOBE NEWSWIRE) — Intrommune Therapeutics, Inc., a clinical-stage biotechnology company committed to developing a patient-friendly treatment platform for people with peanut and other food allergies, today announced the presentation of exploratory efficacy data from the Oral Mucosal Escalation Goal Assessment (OMEGA) Phase 1 safety trial at the 2026 Eastern Allergy…
-
Gaxos Secures Additional Funding from Amazon AWS to Accelerate AI Sales Platform Development
June 02, 2026 08:12 ET | Source: GAXOS.AI INC. Roseland, NJ, June 02, 2026 (GLOBE NEWSWIRE) — Gaxos.ai Inc. (“Gaxos” or the “Company”), a company developing artificial intelligence applications across various high-growth sectors, today announced that Amazon Web Services (“AWS”) has committed additional funding to accelerate Gaxos Labs’ AI-powered sales coaching platform. The additional AWS…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.